THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Biogen: 2 patients get brain disease

Cases are first since Tysabri reintroduced

Biogen Idec of Cambridge reintroduced Tysabri two years ago after pulling it from the market. Biogen Idec of Cambridge reintroduced Tysabri two years ago after pulling it from the market. (Neal Hamberg /Bloomberg News/file 2005)
By Todd Wallack
Globe Staff / August 1, 2008

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

Biogen Idec Inc. said two more patients taking its promising multiple sclerosis drug, Tysabri, appear to have contracted a rare and potentially fatal brain disease, the first cases since the Cambridge biotech company reintroduced the treatment two years ago. (Full article: 599 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass